Analysis Group Review Contributes to ICER Report Findings
November 28, 2016
The Institute for Clinical and Economic Review (ICER), an independent nonprofit research organization, recently commissioned a report on the cost-effectiveness of treatments for moderate-to-severe plaque psoriasis. An Analysis Group team including Managing Principal Eric Wu, Manager Keith Betts, and Associate Junlong Li reviewed the preliminary results of ICER's analysis, and identified and recommended a number of areas to improve. Corresponding changes were made by ICER in its final report, in which ICER noted that “Feedback from these companies resulted in the identification of an error in drug cost, and revisions to the model including addition of drug-specific discontinuation rates, modification of average patient weight, and inclusion of a switching cost for second line targeted drug treatment.” These changes ultimately led to significant improvement in the accuracy of the incremental cost-effectiveness ratio estimates of the psoriasis treatments analyzed for comparative clinical effectiveness.